Emmaus Medical, Inc. Announces Availability of Endari™ for Treatment of Sickle Cell DiseaseDecember 11, 2017 Read More
Emmaus Life Sciences, Inc. to Present Results of Phase 3 Study of EndariTM (L-glutamine oral powder) at 59th American Society of Hematology Annual MeetingNovember 28, 2017 Read More
The U.S. Food & Drug Administration Approves Endari™ (L-glutamine oral powder), the First and Only Treatment for Sickle Cell Disease in Pediatric Patients and First in Nearly 20 Years for AdultsJuly 07, 2017 Read More
FDA Advisory Committee Recommends Approval of Endari™ from Emmaus Life Sciences for the Treatment of Sickle Cell DiseaseMay 24, 2017 Read More
Emmaus Life Sciences Inc. Announces FDA Advisory Committee Meeting for Endari™ for Sickle Cell DiseaseApril 18, 2017 Read More
